Emerging Therapeutic Strategies for Pulmonary Fibrosis  Bisas Muhammad¹, Mahnoor Malik Sohail², Syeda Tahira Zaidi³, Asia Firdous⁴, Ahmad

Bisas Muhammad, Mahnoor Malik Sohail, Syeda Tahira Zaidi, Asia Firdous, Ahmad Basirat, Sabeen Arjumand, Tehseen Mustafa

Emerging Therapeutic Strategies for Pulmonary Fibrosis Bisas Muhammad¹, Mahnoor Malik Sohail², Syeda Tahira Zaidi³, Asia Firdous⁴, Ahmad

Authors

Bisas Muhammad, Mahnoor Malik Sohail, Syeda Tahira Zaidi, Asia Firdous, Ahmad Basirat, Sabeen Arjumand, Tehseen Mustafa

Keywords:

pulmonary fibrosis, TGF-β inhibitor, senolytic, antifibrotic therapy

Abstract

diopathic pulmonary fibrosis (IPF) is a progressive interstitial lung disease with limited lifeexpectancy despite current therapies. Novel approaches including biomolecule-based agents targeting fibrogenic pathways h

References

Justice JN, Nambiar AM, Tchkonia T, et al. Senolytics in idiopathic pulmonary fibrosis: results of a randomized placebo-controlled pilot trial. EBioMedicine. 2023;90:104481. DOI: 10.1016/j.ebiom.2023.104481 (The Lancet)

Downloads

Published

2025-10-28

How to Cite

Bisas Muhammad, Mahnoor Malik Sohail, Syeda Tahira Zaidi, Asia Firdous, Ahmad Basirat, Sabeen Arjumand, Tehseen Mustafa. (2025). Emerging Therapeutic Strategies for Pulmonary Fibrosis Bisas Muhammad¹, Mahnoor Malik Sohail², Syeda Tahira Zaidi³, Asia Firdous⁴, Ahmad . International Journal of Pharmacy Research & Technology (IJPRT), 15(2), 2738–2743. Retrieved from https://www.ijprt.org/index.php/pub/article/view/1111